Back to results
US 2026/0294772 A1Published application
Complex combining a heterocyclic nitrogen biomolecule with a silicic acid, and applications
AssigneeExsymol
InventorMarco CAPPONI
Life of this patent
Estimating the term…
Abstract
The present invention relates to new complexes formed between a) a heterocyclic nitrogen biomolecule and b) a silicic acid, compositions comprising them, and their applications.
Claims16
A complex formed between:
- a) a heterocyclic nitrogen biomolecule selected from purine nucleobases and/or their methylxanthine alkaloid derivatives, free or in N-glycosylated form;
- and
- b) a silicic acid consisting of orthosilicic acid and/or at least one of its water-soluble oligomers;
- said complex being formed via the establishment of at least one weak chemical bond between at least one hydroxyl group of said silicic acid b) and said heterocyclic nitrogen biomolecule a);
- the molar ratio between a) and b) being between about 0.5 and about 15.
2 more elements
A composition comprising at least one complex formed between:
- a) a heterocyclic nitrogen biomolecule selected from purine nucleobases and/or their methylxanthine alkaloid derivatives, free or in N-glycosylated form;
- and
- b) a silicic acid consisting of orthosilicic acid and/or at least one of its water-soluble oligomers;
- said complex being formed via the establishment of at least one weak chemical bond between at least one hydroxyl group of said silicic acid b) and said heterocyclic nitrogen biomolecule a),
- the molar ratio between a) and b) being between about 0.5 and about 15, wherein:
- i) the molar ratio between said heterocyclic nitrogen biomolecule a) and said silicic acid b) is between about 0.5 and about 15, and/or
- ii) the pH of said composition is between about 2.5 and about 4.5.
4 more elements
A use of a silicic acid consisting of orthosilicic acid and/or at least one of its water-soluble oligomers for:
- i) promoting the bioavailability of a heterocyclic nitrogen biomolecule selected from purine nucleobases and/or their methylxanthine alkaloid derivatives, free or in N-glycosylated form;
- and/or
- ii) increasing the solubility of a heterocyclic nitrogen biomolecule selected from purine nucleobases and/or their methylxanthine alkaloid derivatives, free or in N-glycosylated form.
Dependencies are inferred from the claim text.